INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Narrative review / 2014

Lorcaserin and phentermine-topiramate produced modest weight loss alongside diet and exercise in trials, but carry serious safety warnings.

In 2012, the FDA approved lorcaserin and phentermine-topiramate based on 1-year trials alongside recommendations for a calorie-restricted diet and exercise. Patients lost more weight than those on placebo: 3% (95% CI, 3%-4%) more with lorcaserin and 7% (95% CI, 3%-4%) more with phentermine/topiramate. However, both drugs carry warnings for memory, attention, or language problems and depression, alongside other serious drug-specific harms. Neither drug is marketed in Europe due to safety concerns, and required postmarketing safety trials in the US are behind schedule.

Study type
Narrative review / commentary
Who was studied
Patients in 1-year clinical trials for weight loss
What was measured
Weight loss and drug-related harms/safety warnings

THE PAPER

The new weight-loss drugs, lorcaserin and phentermine-topiramate: slim pickings?

Woloshin S, Schwartz LM. JAMA Intern Med, 2014.

PubMed 24515599 ↗DOI 10.1001/jamainternmed.2013.14629 ↗

Heart & arteriesWeight & appetite

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.